Erica Loon, Nicholas Lim, Giovanni A Roldan, John Lake
{"title":"Tenofovir-associated Fanconi Syndrome in liver transplant recipients with hepatitis B: A retrospective case series.","authors":"Erica Loon, Nicholas Lim, Giovanni A Roldan, John Lake","doi":"10.1016/j.ajt.2024.12.015","DOIUrl":null,"url":null,"abstract":"<p><p>Tenofovir-associated Fanconi Syndrome (TAFS) is a proximal renal tubule disorder rarely reported in patients after liver transplantation (LT) for hepatitis B (HBV). In a retrospective review of 79 HBV-LT recipients, 8/66 (12.1%) on tenofovir post-LT developed TAFS. Primary laboratory findings were hypophosphatemia (100%) and proteinuria (87.5%). No patients required renal replacement therapy or died from TAFS. The majority (85.7%) of surviving patients achieved tubular recovery after stopping tenofovir (mean 13 weeks). In conclusion, TAFS is likely underdiagnosed in LT recipients. Regular screening for hypophosphatemia, proteinuria, and glucosuria is recommended for HBV-LT recipients on tenofovir, as most responded well to discontinuation.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9000,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajt.2024.12.015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Tenofovir-associated Fanconi Syndrome (TAFS) is a proximal renal tubule disorder rarely reported in patients after liver transplantation (LT) for hepatitis B (HBV). In a retrospective review of 79 HBV-LT recipients, 8/66 (12.1%) on tenofovir post-LT developed TAFS. Primary laboratory findings were hypophosphatemia (100%) and proteinuria (87.5%). No patients required renal replacement therapy or died from TAFS. The majority (85.7%) of surviving patients achieved tubular recovery after stopping tenofovir (mean 13 weeks). In conclusion, TAFS is likely underdiagnosed in LT recipients. Regular screening for hypophosphatemia, proteinuria, and glucosuria is recommended for HBV-LT recipients on tenofovir, as most responded well to discontinuation.
期刊介绍：
The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide.
The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
